CHEK2 and non-small cell lung carcinoma: In East Asian populations, the odds ratio of NSCLC development in patients with known PGVs was significantly higher when compared to those without, and pathogenic mutations were most commonly observed in BRCA2, followed by CHEK2 and ATM [37].